Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Robertson Stephens Wealth Management LLC

Robertson Stephens Wealth Management LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 32.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,349 shares of the biopharmaceutical company’s stock after buying an additional 1,310 shares during the period. Robertson Stephens Wealth Management LLC’s holdings in Gilead Sciences were worth $433,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of GILD. Nilsine Partners LLC lifted its stake in Gilead Sciences by 1.1% in the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after buying an additional 127 shares during the last quarter. Etesian Wealth Advisors Inc. raised its position in Gilead Sciences by 0.7% in the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after purchasing an additional 128 shares during the last quarter. Financial Counselors Inc. boosted its stake in Gilead Sciences by 1.5% during the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares during the period. Revolve Wealth Partners LLC grew its position in Gilead Sciences by 3.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares during the last quarter. Finally, Institutional & Family Asset Management LLC increased its stake in Gilead Sciences by 10.3% in the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 140 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $64.78 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The stock has a market cap of $80.66 billion, a PE ratio of 179.94, a P/E/G ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a 1 year low of $64.33 and a 1 year high of $87.86. The stock has a fifty day moving average price of $70.72 and a 200 day moving average price of $75.94.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the company posted $1.37 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.75%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on GILD shares. UBS Group lowered their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Morgan Stanley lowered their target price on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Royal Bank of Canada cut their price target on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research note on Friday, April 26th. Cantor Fitzgerald lowered their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Finally, Truist Financial downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.